Motif Neurotech is developing a minimally invasive miniature brain pacemaker for treatment-resistant mental health disorders. The device stimulates the brain to restore healthy circuit activity, initially targeting treatment-resistant depression with plans to expand to bipolar disorder, Alzheimer's disease, and substance use disorder. Founded by Jacob Robinson, PhD (Rice University neuroscience faculty), the company has raised over $30M in venture capital from Arboretum Ventures, KdT Ventures, and Dolby Family Ventures, plus non-dilutive funding from DARPA, NIH, and the UK's ARIA. Clinical trials are expected to begin in H1 2026.